Bladder, Renal, and Testicular Cancers

Saturday, May 5, 2018 from 2:15 PM to 3:15 PM
Available for up to 1.00 hours of CPE credit
Activity Number: 0217-9999-18-088-L01-P

Steven Ludlow, Pharm.D., BCOP, BCPS

  • Faculty: Steven Ludlow, Pharm.D., BCOP, BCPS
    Medical Oncology and Internal Medicine Pharmacist Moffitt Cancer Center Tampa, Florida

Learning Objectives
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular cancer.
2. Determine short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular cancer and his or her caregiver.
3. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.
© 2019 American College of Clinical Pharmacy and American Society of Health‑System Pharmacists